• linkedin
  • Increase Font
  • Sharebar

    Robot linked with improved kidney Ca care

    Kidney cancer patients were more likely to undergo partial nephrectomy when treated in hospitals that were early adopters of robotic surgery, according to a recent report that one leading expert calls “some of the best evidence to date of a favorable impact of surgical robots in urologic care.”

    RELATED: Use of robotic RN rising, despite unclear advantages

    For the study, which was published in Medical Care (2015; 53:71-78), the authors analyzed retrospective data on all nephrectomies from all payers from seven states (Arizona, Florida, Maryland, North Carolina, New York, New Jersey, and Washington) to extract data on 21,569 procedures. They then sorted these procedures by hospital and associated their frequency with the timing of each hospital’s acquisition of surgical robotics.

    The authors reported that by 2008, hospitals that had adopted robotic surgery at the start of the current century (between 2001 and 2004) performed partial nephrectomies in 38% of kidney cancer cases compared to 24% by late adopters (2005 to 2008). Hospitals that had not adopted robotics by 2008 performed partial nephrectomies in 20% of cases.

    “Our study is the first to show, at the hospital level, that more institutional experience with robotic surgery is likely to have resulted in this increase in partial nephrectomy,” said lead author Ganesh Sivarajan, MD, of New York University Langone Medical Center, New York, in a press release from the center.

    “Robotic surgery was not originally designed for treatment of kidney tumors, but what we see here is a case of reinvention, or adaptation,” said senior author Danil V. Makarov, MD, MHS, of NYU Langone. “In this case, the reinvention has served to provide patients increased access to an underutilized, guideline-supported procedure.”


    Next: Dr. Wolf discusses findings

    More recent Urology Times articles

    Primary androgen therapy linked to reduced survival

    Prostate Ca assays show economic, clinical benefits

    Companies acquire rights to low T, IC drugs

    Benjamin P. Saylor
    Saylor is content managing editor for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available